News
Cookies for Cancer
In December 2022, four neighborhood girls from Libertyville, Il, gathered to support cancer research for the Neuroendocrine Tumor Research Foundation with a “Cookies for Cancer”
ENETS Meeting Showcases NETRF-funded Basic and Translational Research
NETRF’s impact on neuroendocrine cancer research was evident at the 20th Annual European Neuroendocrine Tumor Society (ENETS) Conference, held March 22-24 in Vienna. The ENETS
Ancora: An Easier Way to Find a Clinical Trial
A key tenet of NETRF’s mission is to help NET patients navigate the challenges of living with NET cancer. Participating in a clinical trial can
Meet Brittany Holzhauer: NET patient & co-founder of The CureNET Project
We are very grateful to Buckeye Cable Arts Network for allowing us to promote and share this wonderful story reporter Fayth Atkins produced about NET
Be Heard: Share your experience with Carcinoid Syndrome with the FDA
BE HEARD: Share your story with staff of the FDA about your experience or your loved one’s living with #CarcinoidSyndrome (CS). #FDA’s Patient Affairs and NORD are hosting
Out of an enemy, came a calling
NET patient, oncologist, and NETRF Board Member Mark Lewis, MD, is a native Scotsman who moved to Austin, TX as a young man when his
“Collaborative oncology” necessary for Cancer Moonshot success
The Cancer Moonshot’s success relies on ‘collaborative oncology.’ Just last month, the Neuroendocrine Tumor Research Foundation (NETRF) hosted our first in-person/hybrid research symposium since going
Poetic Reflections of a NET Journey
We introduced you to Lilly Pearce back in 2019, when she was about halfway through her senior year of high school and six months post-operation
Study Sites Added to COMPOSE Clinical Trial of PRRT with 177Lu-Edotreotide
Additional US study sites are now participating in an ongoing clinical trial of peptide receptor radionuclide therapy (PRRT) with 177Lu-edotreotide as a first or second
NETRF/NANETS award presented at NANETS 2022 meeting
After being virtual since 2020, the North American Neuroendocrine Tumor Society (NANETS) met in person for its annual meeting in Washington DC in late October. NETRF CEO Elyse Gellerman and Director of Patient Education Jessica Thomas attended the NANETS Symposium to talk with NET specialists, a number of NETRF research grantees, and other NET patient advocacy groups. They joined more than 400 attendees dedicated to better understanding neuroendocrine cancer, improving patient care, and supporting patients through advocacy and education.